

Albus

Albumin Awards Program

ABOUT THE ALBUS AWARDS

Albus is a program whose aim is to foster a scientific network and to increase the knowledge in the use of albumin as a therapeutic product.

By supporting this program Grifols demonstrates its commitment to innovation in this field. We consider the program to be a tangible contribution to the improvement of standards of and benefits to patient care.

ABOUT THE ALBUS PROGRAM

Albus is an annual international awards program focused on innovative ideas involving albumin and its role as a therapeutic product. Proposals may include, but are not limited to, projects on: efficacy, mechanism of action, safety and tolerability, quality of life and pharmacoeconomics.

The program offers 2 awards of €50,000 each to applicants whose proposals best match the program's objectives, as assessed by an independent review committee.

Albus aims to:

- Develop novel concepts in albumin research
- Encourage discovery of beneficial albumin applications.
- Further investigate mechanisms of action or clinical effects in different indications.

WHO CAN APPLY

Scientists or clinicians with an innovative idea relevant to albumin research. Applications are encouraged from both individuals and teams who may be undertaking research at hospitals, universities, or independent institutions.

Applicants must meet the following eligibility requirements to be considered for an Albus award:

- Applicants must present a focused project with goals that can be achieved within 12 months.
- Applicants must be employed or supported by an institution.

REVIEW BOARD

Vicente Arroyo (Chair)

Chairman European Association for the Study of the Liver-Chronic Liver Failure Consortium.

Director Grifols Chair. Barcelona, Spain.

Antonio Artigas

Emerit Director of the Critical Care Center and Full Professor of Applied Physiology. Department of Medicine, UAB. Corporació Sanitaria Parc Taulí, Sabadell (Barcelona), Spain.

Luciano Gattinoni

Professor in Anesthesiology, Emergency and Intensive Care Medicine. Georg-August University of Göttingen. Göttingen, Germany.

Marco Ranucci

Head of the Cardiothoracic Anesthesia Department. Director of Clinical Research in the Dept. of Anesthesia and Intensive Care. IRCCS Policlinico San Donato. Milan, Italy.

Rajiv Jalan

Professor of Hepatology. University College London. Institute for Liver and Digestive Health Royal Free Hospital. London, UK.

Greg Martin

Associate Professor of Medicine and Associate Division Director for Critical Care. Emory University. Atlanta, GA, USA.

Bruce Spiess

Professor and Associate Chair (Research). Department of Anesthesiology. University of Florida College of Medicine. Gainesville, FL, USA.

Francisco Mota, Pharm D, MSc (non-voting Executive Secretary) Senior Manager Medical Affairs -Intensive Care - EU/ROW Grifols S.A.

EVALUATIONS AND SELECTION OF RESEARCH PROPOSALS

Applications are evaluated based on merit, innovation, impact, and research environment/qualification of the applicant. A Review Board of external experts and one Grifols expert in albumin (secretary) assess and rank the grant applications.

TIMELINES FOR THE ALBUS PROGRAM*

Start of Letter of Intent submission period: **October 3rd, 2017**

Deadline for reception of Letters of Intent: **April 16th, 2018**

Announcement of candidates selected to submit a Full Proposal:

May 16th, 2018

Deadline for Full Proposal submission: **June 18th, 2018**

Awardees names publication online: **July 18th, 2018**

Awards Ceremony: **Fall, 2018**

Additional information on the grant program and application forms can be found on our website: www.grifols.com

* This schedule is subject to change. Changes will be reflected in our website.

NOT VALID FOR PRINTING! Low resolution PDF file. For high resolution files, please contact Corporate Communications corporatecomms@grifols.com

GRIFOLS SCIENTIFIC AWARDS











GRIFOLS